Amarin Corporation/$AMRN
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Amarin Corporation
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
Ticker
$AMRN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Dublin 2, Ireland
Employees
-
ISIN
US0231114044
Website
AMRN Metrics
BasicAdvanced
$346M
-
-$4.40
0.67
-
Price and volume
Market cap
$346M
Beta
0.67
52-week high
$17.18
52-week low
$8.32
Average daily volume
144K
Financial strength
Current ratio
3.529
Quick ratio
2.392
Long term debt to equity
1.676
Total debt to equity
2.183
Interest coverage (TTM)
-8,356.43%
Profitability
EBITDA (TTM)
-55.514
Gross margin (TTM)
51.88%
Net profit margin (TTM)
-41.07%
Operating margin (TTM)
-27.32%
Effective tax rate (TTM)
-7.00%
Management effectiveness
Return on assets (TTM)
-5.06%
Return on equity (TTM)
-17.25%
Valuation
Price to revenue (TTM)
1.609
Price to book
0.73
Price to tangible book (TTM)
0.76
Price to free cash flow (TTM)
-11.155
Free cash flow yield (TTM)
-8.96%
Free cash flow per share (TTM)
-149.98%
Growth
Revenue change (TTM)
-22.83%
Earnings per share change (TTM)
69.17%
3-year revenue growth (CAGR)
-26.34%
10-year revenue growth (CAGR)
13.72%
3-year earnings per share growth (CAGR)
57.78%
10-year earnings per share growth (CAGR)
-5.61%
Bulls say / Bears say
Amarin's exclusive license and supply agreement with Recordati to commercialize VAZKEPA® across 59 European countries includes a $25 million upfront payment and potential milestone payments up to $150 million, positioning the company for significant revenue growth in Europe. (stocktitan.net)
The company reported a 184% increase in European product revenue to $5.4 million in Q1 2025, indicating successful market penetration and potential for continued growth in the region. (panabee.com)
Amarin maintains a strong financial position with nearly $300 million in cash and no debt, providing stability and resources to invest in growth initiatives. (stocktitan.net)
U.S. product revenue declined by 26% year-over-year to $35.7 million in Q1 2025, primarily due to intense generic competition and the loss of a major PBM contract, leading to a substantial decrease in market share to 42%. (panabee.com)
The company reported a net loss of $15.7 million in Q1 2025, a 57% increase from the previous year, indicating that revenue declines significantly outpaced expense reductions. (panabee.com)
Amarin's stock price has experienced significant volatility, with a 26% decline in March 2025, reflecting market concerns over the company's revenue trajectory and profitability trends. (simplywall.st)
Data summarised monthly by Lightyear AI. Last updated on 28 Jun 2025.
AMRN News
AllArticlesVideos
RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE
GlobeNewsWire·1 week ago
Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewsWire·2 months ago
Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Amarin Corporation stock?
Amarin Corporation (AMRN) has a market cap of $346M as of July 04, 2025.
What is the P/E ratio for Amarin Corporation stock?
The price to earnings (P/E) ratio for Amarin Corporation (AMRN) stock is 0 as of July 04, 2025.
Does Amarin Corporation stock pay dividends?
No, Amarin Corporation (AMRN) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Amarin Corporation dividend payment date?
Amarin Corporation (AMRN) stock does not pay dividends to its shareholders.
What is the beta indicator for Amarin Corporation?
Amarin Corporation (AMRN) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.